From $7.20 to $4.11, straight shot down in 3 months. Simply unbelievable really! As if a drug candidate had been rejected. Plenty of micro pharmas with PI and PII drugs with market caps 2-3X that of ARNA. Management is really to blame and no one else. Failure to execute. Failure to generate institutional or retail interest. Failure to communicate any information with clarity. Failure is JL's middle name.
Jack et al. missing in action. Shareholders left scratching their heads.
You are a former WS exec but cannot for the life of you spell dollar? What is a "doller?" Pleural form of CEO would be CEOs not CEO's. Ceo's would be possesive right? Also its Colorado, not Colorato!
I'm long but the bs has got to stop!
Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
So much for intellectual property people. Yet another nail in the coffin of VVUS. This was a known issue and funny how lawsuit was filed on Friday and settled over the weekend.
You should know by now that you cannot depend or trust ARNA mgmt for really anything.
Market at 2 year highs and ARNA at 2 year lows, as if it did not have a product to sell, as if it had no cash, as if it had no patents or intellectual property.
Amazes me how stocks like ACAD with only 1 candidate yet to be approved and no real R&D have a market cap of over $2B and ARNA struggles to maintain a market cap of $900M.
Amazes me how stock is down over 40% despite short interest dropping 40%, 25M shares over 8 months!
Amazes me how Jack is still CEO given the absolute failure to increase shareholder value and with every turn, does his best to undermine the retail investor.
Amazes me that I am still holding shares. Someone slap me I must be having a bad dream! Ha ha ha!
Correct. This was their initial estimate from their report from early 2013. I have not seen their updated numbers.
Correction! Sorry. Here it is from their report from 2013. I have not seen the revised report if it even exists. Price target still $4.
Exhibit 1: US Revenue Model
Calendar years 2013 2014 2015 2016 2017 2018 2019 2020
Total patients on Belviq (000s) 92 303 480 599 675 725 752 758
Revenue / patient ($) $918 $936 $955 $974 $994 $1,014 $1,034 $1,054
Total US revenue ($M) $84 $284 $459 $584 $671 $734 $778 $799
From the Credit Suisse report, for 2015 Arena is expected to deliver $325 million. I have not seen any revised numbers for 2015 or 2016.
Who cares? Last countdown had no effect on ARNA share price anyhow. Who cares? OREX delayed, ARNA unchanged. OREX approved, ARNA probably no change yet again.
Devil is always in the details. Right folks?
ARNA is a buy and hold right here right now.
Russo also represents Puma Biotechnology, PBYI, of recent 300% gain fame with a $7B market cap and no FDA approved product to speak of. Yet lowly ARNA struggles to maintain a market cap of a mere $900M.
Russo also represents Puma Biotechnology, Inc. (PBYI), of recent 300% gain fame without FDA approved product and $7B market cap! Wow!
I can only pray they are as successful as the Dream Team from GALE. ROFLMAO! Can you say 300% gain in just a few months?